A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

NCT04424641 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

48

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated due to MTD was reached

Conditions

Locally Advanced or Metastatic Solid Tumor(s)
Prostate Cancer
Esophageal Cancer
Triple Negative Breast Cancer (TNBC)
Squamous Cell Carcinoma of Head and Neck (SCCHN)
Non-small Cell Lung Cancer (NSCLC)
Bladder Cancer
Uterine Cancer

Interventions

BIOLOGICAL: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.

Sponsor

Genmab

Collaborators

[object Object]